PBLS
Parabilis Medicines, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Parabilis Medicines, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Parabilis Medicines, Inc.
28.32
Linked news
News| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | RA Capital ManagementRA Capital Management | $791.9M | 29.22% | new | |
| 2 | FMRFMR | $281.7M | 10.39% | new | |
| 3 | Arch VentureArch Venture | $175.5M | 6.48% | new | |
| 4 | venBio PartnersvenBio Partners | $144.1M | 5.32% | new | |
| 5 | AlphabetAlphabet | $134.6M | 4.97% | new | |
| 6 | Nextech InvestNextech Invest | $127.6M | 4.71% | new | |
| 7 | Cormorant Asset ManagementCormorant | $126.3M | 4.66% | new | |
| 8 | Regeneron PharmaceuticalsRegeneron Pharmaceuticals | $114.0M | 4.21% | new | |
| 9 | SirenSiren | $81.9M | 3.02% | new | |
| 10 | Farallon Capital ManagementFarallon | $64.8M | 2.39% | new | |
| 11 | Jupiter TopcoJupiter Topco | $62.7M | 2.31% | — | |
| 12 | Frazier Life Sciences ManagementFrazier Life Sciences | $52.6M | 1.94% | new | |
| 13 | Deerfield ManagementDeerfield | $51.5M | 1.90% | new | |
| 14 | General Catalyst Group ManagementGeneral Catalyst | $43.8M | 1.62% | new | |
| 15 | General AtlanticGeneral Atlantic | $42.1M | 1.55% | new | |
| 16 | Soleus Capital ManagementSoleus | $40.1M | 1.48% | new | |
| 17 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $35.6M | 1.32% | new | |
| 18 | Vanguard Capital ManagementVanguardindex-like | $31.7M | 1.17% | new | |
| 19 | JPMorgan ChaseJPMorgan Chase | $30.4M | 1.12% | new | |
| 20 | Foresite Capital Management VIForesite Capital Management VI | $27.3M | 1.01% | new | |
| 21 | Catalio Capital ManagementCatalio | $22.6M | 0.83% | new | |
| 22 | AlliancebernsteinAlliancebernstein | $22.2M | 0.82% | new | |
| 23 | T. Rowe Price AssociatesT. Rowe Price | $20.6M | 0.76% | new | |
| 24 | Casdin CapitalCasdin Capital | $17.7M | 0.65% | new | |
| 25 | VR AdviserVR Adviser | $17.1M | 0.63% | new |
79 managers report $2.7B of Parabilis Medicines on form 13F for the quarter ended Jun 30 '26. 13 of them hold 80% of it; RA Capital Management is largest at 29.22%.
Expected move
No implied move.
No implied move.
No implied move.